Beacon Investment Advisory Services Inc. Has $37.84 Million Holdings in Insulet Co. (NASDAQ:PODD)

Beacon Investment Advisory Services Inc. cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 2.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 162,584 shares of the medical instruments supplier’s stock after selling 3,972 shares during the quarter. Insulet accounts for 1.6% of Beacon Investment Advisory Services Inc.’s holdings, making the stock its 19th largest position. Beacon Investment Advisory Services Inc. owned 0.23% of Insulet worth $37,841,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Marshall Wace LLP bought a new position in Insulet during the 2nd quarter worth $99,978,000. Baillie Gifford & Co. grew its holdings in shares of Insulet by 30.8% during the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after purchasing an additional 443,783 shares in the last quarter. Mizuho Securities USA LLC increased its position in shares of Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after purchasing an additional 320,416 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Barclays upped their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Finally, Canaccord Genuity Group upped their price objective on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Price Performance

PODD stock opened at $266.78 on Monday. The company has a market capitalization of $18.71 billion, a P/E ratio of 45.68, a PEG ratio of 4.08 and a beta of 1.22. The company has a fifty day moving average price of $244.40 and a 200-day moving average price of $214.14. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.